Oral/sublingual phleum pretense grass tablet (Grazax/Grastek) to treat allergic rhinitis in the USA

Expert Review of Clinical Immunology

Volumn 10, Issue 11, 2014, Pages 1437-1451

  Nelson, Harold S ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

AIT; allergy immunotherapy; grass immunotherapy; SCIT; SLIT; subcutaneous immunotherapy; sublingual immunotherapy

Indexed keywords

GRASS POLLEN EXTRACT; STALLERGEN; GRASS POLLEN VACCINE; PLANT EXTRACT;

ALLERGIC RHINITIS; APPLICATION SITE REACTION; ARTICLE; COST EFFECTIVENESS ANALYSIS; CROSS REACTION; DOSE RESPONSE; DRUG APPROVAL; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRY THROAT; DYSPEPSIA; EAR PRURITUS; EDEMA; FOOD AND DRUG ADMINISTRATION; HUMAN; LIP DISEASE; LIP PRURITUS; LIP SWELLING; META ANALYSIS (TOPIC); MOUTH EDEMA; MULTICENTER STUDY (TOPIC); NONHUMAN; OCULAR PRURITUS; ORAL IMMUNOTHERAPY; ORAL PARESTHESIA; ORAL PRURITUS; OROPHARYNX PAIN; PHARMACODYNAMICS; PHARYNX DISEASE; PHARYNX EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEUM PRATENSE; PRESCRIPTION; PRURITUS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SWELLING; TABLET; THROAT IRRITATION; TONGUE DISEASE; TONGUE PRURITUS; TONGUE SWELLING; UNITED STATES; CHEMISTRY; IMMUNOLOGY; RHINITIS, ALLERGIC; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; HUMANS; PHLEUM; PLANT EXTRACTS; RHINITIS, ALLERGIC; SUBLINGUAL IMMUNOTHERAPY; UNITED STATES;

EID: 84911478349     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.963556     Document Type: Article

References (65)

1. Nelson HS. Some highlights of the first century of immunotherapy. Ann Allergy Asthma Immunol 2011;107:417-21
2. Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 2008;29:600-8
3. Bauchau V, Durham S.R. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64
4. Meltzer EO, Blaiss MS, Naclerio RM, et al. Burden of allergic rhinitis: allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy asthma Proc 2012;33: S113-41
5. Meltzer EO, Blaiss MS, Derebery MJ, et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin Immunol 2009;124:S43-70
6. Hoppin JA, Jaramillo R, Salo P, et al. Questionnaire predictors of atopy in a US population sample: findings from the National Health and Nutrition Examination Survey, 2005-2006. Am J Epidemiol 2011;173:544-52
7. Meltzer EO, Nathan R, Derebery J, et al. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: Findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc 2009;30:244-54
8. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004;116:338-44
9. Benninger M, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol 2010;104:13-29
10. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1572-3
11. Nelson HS. Subcutaneous injection immunotherapy for optimal effectiveness. Immunol Allergy Clin North Am 2011;31: 211-26
12. Cox L, Nelson H, Lockey R. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011;127: S1-S55
13. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014;7:6-doi 10.1186/1939-4551-7-6.
14. Lin SY, Eekosima N, Kim MJ, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 2013;309:1278-88
15. Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol 2009;103:451-9
16. Sikora JM, Tankersley MS. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: a follow-up study. Ann Allergy Asthma Immunol 2013;110:194-7
17. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120: 1338-45
18. Didier A, Malling HJ, Worm M, et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy 2013;43:568-77.
19. Oralair: Food and Drug Administration Allergenic Products Advisory Committee Briefing Document. Available from: www. fda.gov/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/allergenicproductsadvisorycommittee/ucm367268.htm 11-12 December 2013
20. Cox L, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a U.S. study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012;130:1327-34
21. Weber RW. Aerobiology of outdoor allergens. In: Adkinson NF Jr, Bochner BS, Burks AW, Busse WW, Holgate ST, Lemanske RF Jr, O'Hehir RE, editors. Middleton's allergy: principles and practice. Elsevier/Saunders; Philadelphia, USA: 2014
22. Arbes SJ, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2005;116:377-83
23. Chabre H, Bouyon B, Huet A, et al. Molecular variability of group 1 and 5 grass pollen allergens between Pooideae species: implications for immunotherapy. Clin Exp Allergy 2009;40:505-19
24. Gangl K, Niederberger V, Valenta R. Multiple grass mixes as opposed to single grasses for allergen immunotherapy in allergic rhinitis. Clin Exp Allergy 2013;43: 1202-16
25. Martin BG, Mansfield LE, Nelson HS. Cross-allergenicity among the grasses. Ann Allergy 1985;54:99-104
26. Heji C, Wurtzen PA, Kleine-Tebbe J, et al. Phleum pretense alone is sufficient for allergen-specific immunotherapy against allergy to Pooideae grass pollens. Clin Exp Allergy 2009;39:752-9
27. Archila LD, DeLong JH, Wambre E, et al. Grass-specific CD4+ T-cells exhibit varying degrees of cross-reactivity. Clin Exp Allergy 2014;44(7):986-98
28. Varney VA, Gaga M, Frew AJ, et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:265-9
29. Frostad AB, Grimmer O, Sandvik L, et al. Clinical effects of hyposensitization using a purified allergen preparation from Timothy pollen as compared to crude aqueous extracts from timothy pollen and a four-grass pollen mixture respectively. Clin allergy 1983;13:337-57
30. Martinez-Cocera C, Sastre J, Cimarra M, et al. Immunotherapy with a Phleum pretense allergen extract induces an immune response to a grass-mix allergen extract. J Investig Allergol Clin Immunol 2010;20: 13-19
31. Durham SR, Emminger WE, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012;129:717-25
32. Grastek-. prescribing information Merck Sharp & Dohme Corp. a subsidiary of Merck & Co, Inc, Whitehouse Station, NJ 08889, USA. 2014
33. Bagnasco M, Altrinetti V, Pesce G, et al. Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol 2005;138:197-202
34. Calderon MA, Simons FER, Malling H-J, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012;67:302-11
35. Bohle B, Kinaciyan T, Gerstmayr M, et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007;120:707-13
36. MK-7743 timothy Grass Pollen Extract Tablets Advisory Committee Meeting Briefing Document. Available from: www. fda.gov/AllergenicProductsAdvisory Committee/2013MeetingMaterial/. 11-12 December 2013.
37. Malling HJ, Lung L, Ipsen H, Poulsen L. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol 2006;16: 162-8
38. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006;61:181-4
39. Calderon M, Essendrop M. Specific immunotherapy with high dose SQ standardized grass allergen tablets was safe and well tolerated. J Investig Allergol Clin Immunol 2006;16:338-44
40. Ibanez MD, Kaiser F, Knecht R, et al. Safety of specific sublingual immunotherapy with sQ standardized grass allergen tablets in children. Ped Allergy Immunol. 2007;18: 516-22
41. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802-9
42. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434-40
43. Murphy K, Gawchik S, Bernstein D, et al. A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma. J Negat Results Biomed 2013;12:10-19
44. Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass allergic immunotherapy tablet in North American adults. J Allergy Clin Immunol 2011;127: 72-80
45. Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011;127:64-71
46. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167-73
47. Maloney J, Bernstein DI, Nelson H, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol 2014;112:146-53.
48. Durham SR, Nelson HS, Nolte H, et al. Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. Allergy 2014;69:617-23
49. Calderon MA, Birk AO, Andersen JS, Durham S.R. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 2007;62:958-61
50. Nelson H, Blaiss M, Nolte H, et al. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono-and polysensitized subjects. Allergy 2013;68:252-5
51. Dahl R, Stendert A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006;61:185-90
52. Reich K, Gessner C, Kroker A, et al. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: A Phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis. Clin Therapeut 2011;33:828-40
53. Schwab J-A, Wolf H, Schnitker J, Wustenberg E. Safety and tolerability of an intra-seasonal initiation of the SQ-standardised grass allergy immunotherapy tablet: a non-interventional observational study investigating the feasibility during routine administration. Clin Drug Investig 2013;33:719-26
54. Wessel F, Chartier A, Meunier J-P, Magnan A. Safety and tolerability of an SQstandardized grass allergy immunotherapy tablet (GRAZAX) in a real-life setting for three consecutive seasons-the GRAAL Trial. Clin drug Investig 2012;32:451-63
55. Frew AJ, Powell RJ, Corrigan CJ, Durham S.R. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319-25
56. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, Year 3: what practices modify the risk of systemic reactions Ann Allergy Asthma Immunol 2013;110:274-8
57. Dretzke J, Meadows A, Novielli N, et al. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol 2013;131:1361-7
58. De Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009;64:963-4
59. Bachert C, Vestenbaek U, Christensen J, et al. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis-a Northern European perspective. Clin Exp Allergy 2007;37:772-9.
60. Nasser S, Vestenbaek U, Bariot-Mathiot A, Poulsen PB. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy 2008;63:1624-9
61. Ronaldson S, Taylor M, Bech PG, et al. Economic evaluation of SQ-standardized grass allergy immunotherapy tablet. Clinicoecon Outcomes Res 2014;6:187-96
62. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the Pat study. Allergy 2007;62:943-8
63. Kiel MA, Roder E, van Wijk RG, et al. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol 2013;132:353-60.
64. Alesina R, Milani M, Pecora S. A multicenter, randomized, parallel-group trial assessing compliance, tolerability, safety, and efficacy to treatment with grass allergy tablets in 261 patients with grass pollen rhinoconjunctivitis. J Allergy 2012;2012:673502
65. Valovirta E, Berstad AKH, de Blic J, et al. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. Clin Therapeut 2011;33:1537-46